百利天恆(688506.SH):2024年淨利潤36.58億元 同比扭虧爲盈
格隆匯2月27日丨百利天恆(688506.SH)公佈2024年年度業績快報,報告期內,公司實現營業總收入582,271.28萬元,同比增長936.31%;實現歸屬於母公司所有者的淨利潤365,793.43萬元,較上年同期增加443,843.32萬元;歸屬於母公司所有者的扣除非經常性損益的淨利潤360,364.96萬元,較上年同期增加441,639.83萬元。
報告期內,公司2024年度營業總收入較上年同期大幅增加,歸屬於母公司所有者的淨利潤、歸屬於母公司所有者的扣除非經常性損益的淨利潤與上年同期相比實現扭虧爲盈,主要系公司收到核心產品BL-B01D1(EGFR×HER3雙抗ADC)的海外合作夥伴百時美施貴寶(BMS)基於合作協議支付的8億美元不可撤銷、不可抵扣首付款所致。同時,公司持續聚焦重點戰略領域,加大研發投入,穩步推進創新生物藥的研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.